Moderna Regains Rights to RSV Vaccine From Merck
October 08 2020 - 7:56AM
Dow Jones News
By Dave Sebastian
Moderna Inc. said it has regained rights to the respiratory
syncytial virus vaccine from Merck & Co. Inc., allowing the
company to develop the vaccine in adults.
The vaccine, named mRNA-1172 and known as MSD outside the U.S.
and Canada, uses a Merck lipid nanoparticle and entered early-stage
development last year. Merck will complete the phase-one study,
Moderna said.
RSV is a pathogen that leads to cold-like symptoms, according to
the Centers for Disease Control and Prevention. It could cause more
severe infections such as bronchiolitis and pneumonia, the CDC
said.
Moderna also said it is starting dosing in the phase one study
of mRNA-1345, its solely owned RSV vaccine candidate. The dosing
will start in adults, it said.
Merck's RSV efforts will go toward its antibody program that is
in phase-two development, Moderna said.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
October 08, 2020 07:41 ET (11:41 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From May 2023 to May 2024